Document:

Exh. 10.7 - Quiros Note Purchase Agreement dated March 30, 2006

THIS NOTE PURCHASE AGREEMENT IS BEING ISSUED TO WILLIAM H. QUIROS AS A CARVE OUT
FROM THE NOTE PURCHASE  AGREEMENT  BETWEEN  MEDICAL MEDIA  TELEVISION,  INC. AND
CAPITALSMART,  LLC ("CAPITALSMART  NOTE PURCHASE  AGREEMENT") DATED FEBRUARY 14,
2006.  PER AN  AGREEMENT  BETWEEN  THE  PRINCIPALS  OF  CAPITALSMART,  LLC,  THE
CAPITALSMART NOTE PURCHASE  AGREEMENT WAS CANCELLED AND INDIVIDUAL NOTE PURCHASE
AGREEMENTS  WERE ISSUED IN LIEU  THEREOF,  EACH IN THE NAME OF A  PRINCIPAL  (OR
ENTITY CONTROLLED BY A PRINCIPAL) OF CAPITALSMART.

                             NOTE PURCHASE AGREEMENT

         This NOTE PURCHASE AGREEMENT (this "Agreement"),  dated as of March 30,
2006,  is entered into by and among Medical  Media  Television,  Inc., a Florida
corporation (the "Company"),  and William H. Quiros (the  "Purchaser"),  for the
issuance  and  sale to the  Purchaser  of the  Note (as  defined  below)  of the
Company, in the manner, and upon the terms,  provisions and conditions set forth
in this Agreement.

         WHEREAS,  the parties  desire  that,  upon the terms and subject to the
conditions  contained herein,  the Company shall issue and sell to the Purchaser
and the Purchaser shall purchase the Note;

         WHEREAS,  such  issuance  and sale  will be made in  reliance  upon the
provisions of Section 4(2) and/or Rule 506 of Regulation D  ("Regulation  D") of
the  United  States  Securities  Act  of  1933,  as  amended,   and  regulations
promulgated thereunder (the "Securities Act"), or upon such other exemption from
the  registration  requirements  of the  Securities Act as may be available with
respect to the purchase of the Note to be made hereunder.

         NOW, THEREFORE, in consideration of the representations, warranties and
agreements  contained  herein and other  good and  valuable  consideration,  the
receipt and legal adequacy of which is hereby  acknowledged by the parties,  the
Company and the Purchaser hereby agree as follows:

         1.   Purchase and Sale of Note.

                  (a) Terms of Note: Upon the following terms and subject to the
conditions  contained herein, the Company shall issue and sell to the Purchaser,
and the Purchaser shall purchase from the Company, a convertible promissory note
in the  aggregate  principal  amount of $450,000  (the  "Purchase  Price")  made
through  installments,  in  substantially  the form attached hereto as Exhibit A
(the "Note").

         The  outstanding  principal  amount of the Note,  plus any  accrued but
unpaid interest  thereon,  shall be due and payable in cash on the Maturity Date
(as defined in the Note);  provided,  however, the Purchaser shall have the sole
option to convert on the Maturity Date the outstanding  principal  amount of the
Note plus any accrued but unpaid  interest  into such number of shares of Common
Stock of the  Company,  par value $.0005 per share (the  "Common  Stock"),  at a
Conversion  Price equal to a twenty percent (20%)  discount to the  then-current
market  price  based on the  average  closing  price  for the  twenty  (20) days
immediately preceding the conversion, but in no event shall the Conversion Price
be less than $0.166.  The Note shall not be convertible  until the Maturity Date
and shall not be  convertible  such that the  Investor's  overall  Common  Stock
ownership   position  in  the  Company   exceeds  4.99%  (the   "Ownership   Cap
Restriction"); provided, however, that upon the holder of the Note providing the
Company with  sixty-one  (61) days notice (the "Waiver  Notice") that the holder
would like to waive the  Ownership  Cap  Restriction  with  regard to any or all
shares of Common Stock issuable upon exercise of the  conversion  feature of the
Note, this Ownership Cap  Restriction  will be of no force or effect with regard
to all or a portion of the Note  referenced in the Waiver  Notice,  and provided
further that this  Ownership  Cap  Restriction  shall be of no further  force or
effect during the sixty-one  (61) days  immediately  preceding the expiration of
the term of the Note.
<PAGE>

          The Note shall bear  interest  at a rate of twenty  percent  (20%) per
annum. Until such time as all installments representing an aggregate of $450,000
have been paid to the Company by the Payee,  interest hereunder shall be paid on
a quarterly  basis with the said interest  payment(s)  being applied  toward the
balance  remaining  unpaid  ("Applied  Interest").  At such  time as the  entire
$450,000 has been  received by the Company  [via cash  payments  and/or  Applied
Interest],  then all future  interest shall accrue,  but will not become due and
payable until the Maturity Date.

         With the consent of both the Company and the Investor,  the Note may be
extended for an  additional  twelve (12) months,  with the terms of the interest
payments  remaining  the same as above.  The  Company  has the option to pay the
principal  amount of this Note plus  accrued  but unpaid  interest  and  Applied
Interest in a cash payment at any time prior to the Maturity Date.

                  (b)  Issuance  of  Warrants:   The  Investor  will  be  issued
1,125,000 warrants to purchase Common Stock of the Company (the "Warrants"). The
Warrants  shall  be  issued  at the end of each  calendar  quarter  based on the
increase in the amount due under the Note for that period.  The  Warrants  shall
have a term of five (5) years and shall have an  exercise  price  equal to $0.75
per share (the "Exercise  Price").  The Warrants  shall not be exercisable  such
that the  Investor's  overall  Common  Stock  ownership  position in the Company
exceeds 4.99%.

                  (c) In  consideration  of and in  express  reliance  upon  the
representations,  warranties, covenants, terms and conditions of this Agreement,
the Company  agrees to issue and sell to the Purchaser and the Purchaser  agrees
to purchase the Note.  The closing under this Agreement  (the  "Closing")  shall
take place at the offices of Medical Media Television, Inc., 8406 Benjamin Road,
Suite C, Tampa,  Florida 33634 upon the  satisfaction  of each of the conditions
set forth in Sections 4 and 5 hereof (the "Closing Date").

                  (d)  The   Investor  is  aware  that  the   Company   filed  a
Registration  Statement  on Form SB-2 which was  approved  by the  Securities  &
Exchange  Commission  on March 1, 2006 and that a total of  2,500,000  shares of
Common Stock were  reserved and  registered  for the  conversion of the original
CapitalSmart   Convertible   Promissory  Note  for   $1,000,000.   The  Investor
acknowledges  and understands  that 1,125,000  shares of Common Stock previously
registered has been allocated toward the conversion of this Note (the "Allocated
Shares") and that any shares of Common  Stock  issued to the  Investor  upon the
conversion  of this Note in excess of the  Allocated  Shares shall have standard
piggyback registration rights.

         2.   Representations,  Warranties  and Covenants of the  Purchaser. The
Purchaser  hereby makes the  following  representations  and  warranties  to the
Company, and covenants for the benefit of the Company:

                  (a)  If  the  Purchaser  is  an  entity,  the  Purchaser  is a
corporation,  limited  liability  company or partnership  duly  incorporated  or
organized,  validly  existing  and  in  good  standing  under  the  laws  of the
jurisdiction of its incorporation or organization.

                                       -2-
<PAGE>

                  (b) This Agreement has been duly authorized,  validly executed
and  delivered  by the  Purchaser  and is a  valid  and  binding  agreement  and
obligation of the Purchaser enforceable against the Purchaser in accordance with
its terms, subject to limitations on enforcement by general principles of equity
and by bankruptcy or other laws affecting the  enforcement of creditors'  rights
generally, and the Purchaser has full power and authority to execute and deliver
this Agreement and the other agreements and documents contemplated hereby and to
perform its obligations hereunder and thereunder.

                  (c) The Purchaser understands that no Federal, state, local or
foreign  governmental  body or  regulatory  authority  has made any  finding  or
determination relating to the fairness of an investment in any of the Securities
and that no Federal,  state,  local or foreign  governmental  body or regulatory
authority  has  recommended  or  endorsed,  or will  recommend  or endorse,  any
investment in any of the  Securities.  The Purchaser,  in making the decision to
purchase the Securities,  has relied upon independent  investigation  made by it
and has not relied on any information or representations made by third parties.

                  (d) The Purchaser  understands  that the  Securities are being
offered and sold to it in reliance on specific  provisions  of Federal and state
securities  laws and that the Company is relying  upon the truth and accuracy of
the representations,  warranties, agreements, acknowledgments and understandings
of the Purchaser set forth herein for purposes of qualifying for exemptions from
registration under the Securities Act, and applicable state securities laws.

                  (e) The Purchaser is an "accredited investor" as defined under
Rule 501 of Regulation D promulgated under the Securities Act.

                  (f) The Purchaser is and will be acquiring the  Securities for
its own account,  and not with a view to any resale or  distribution of the Note
in  whole or in part,  in  violation  of the  Securities  Act or any  applicable
securities laws.

                  (g) The offer and sale of the  Securities  is  intended  to be
exempt from  registration  under the  Securities  Act, by virtue of Section 4(2)
and/or Rule 506 of  Regulation  D  promulgated  under the  Securities  Act.  The
Purchaser understands that the Securities purchased hereunder have not been, and
may  never  be,  registered  under  the  Securities  Act  and  that  none of the
Securities can be sold or transferred unless they are first registered under the
Securities Act and such state and other  securities laws as may be applicable or
in the opinion of counsel for the Company an exemption from  registration  under
the  Securities  Act is  available  (and  then  the  Securities  may be  sold or
transferred  only in compliance with such exemption and all applicable state and
other securities laws).

         3.  Representations,  Warranties  and  Covenants  of the  Company.  The
Company represents and warrants to the Purchaser,  and covenants for the benefit
of the Purchaser, as follows:

                  (a) The Company has been duly  incorporated,  validly  exists,
and is in good  standing  under  the laws of the  State of  Florida,  with  full
corporate  power and authority to own,  lease and operate its  properties and to
conduct  its  business  as  currently  conducted,  and is  duly  registered  and
qualified to conduct its business and is in good  standing in each  jurisdiction
or place  where the nature of its  properties  or the  conduct  of its  business
requires  such  registration  or  qualification,  except  where the  failure  to
register or qualify would not have a Material  Adverse  Effect.  For purposes of
this Agreement, "Material Adverse Effect" shall mean any effect on the business,
results of operations,  prospects,  assets or financial condition of the Company
that is material and adverse to the Company and its  subsidiaries and affiliates
and/or  any  condition,  circumstance,  or  situation  that  would  prohibit  or
otherwise  materially  interfere  with the ability of the Company from  entering
into and performing any of its  obligations  under this Agreement or the Note in
any material respect.

                                       -3-
<PAGE>

                  (b)  The  Note  has  been  duly  authorized  by all  necessary
corporate  action  and,  when paid for or issued  in  accordance  with the terms
hereof, the Note shall be validly issued and outstanding,  free and clear of all
liens,  encumbrances  and  rights of refusal  of any kind.  When the  Conversion
Shares are issued and paid for in  accordance  with the terms of this  Agreement
and as set  forth  in the  Note,  such  shares  will be duly  authorized  by all
necessary  corporate action and validly issued and  outstanding,  fully paid and
nonassessable,  free and clear of all liens,  encumbrances and rights of refusal
of any kind and the holders shall be entitled to all rights accorded to a holder
of Common Stock.

                  (c) The Note and this Agreement (the "Transaction  Documents")
have been duly  authorized,  validly  executed  and  delivered  on behalf of the
Company  and is a valid and  binding  agreement  and  obligation  of the Company
enforceable  against  the  Company  in  accordance  with its  terms,  subject to
limitations on enforcement by general  principles of equity and by bankruptcy or
other laws affecting the  enforcement of creditors'  rights  generally,  and the
Company has full power and  authority  to execute  and  deliver the  Transaction
Documents  and the other  agreements  and documents  contemplated  hereby and to
perform its obligations hereunder and thereunder.

                  (d) The  execution and delivery of the  Transaction  Documents
and the consummation of the  transactions  contemplated by this Agreement by the
Company,  will not (i) conflict with or result in a breach of or a default under
any  of  the  terms  or  provisions   of,  (A)  the  Company's   certificate  of
incorporation  or by-laws,  or (B) of any material  provision of any  indenture,
mortgage,  deed of trust or other material  agreement or instrument to which the
Company is a party or by which it or any of its material properties or assets is
bound, (ii) result in a violation of any material provision of any law, statute,
rule,  regulation,  or any existing applicable decree,  judgment or order by any
court,  Federal  or  state  regulatory  body,  administrative  agency,  or other
governmental body having  jurisdiction over the Company,  or any of its material
properties  or  assets or (iii)  result in the  creation  or  imposition  of any
material lien, charge or encumbrance upon any material property or assets of the
Company or any of its  subsidiaries  pursuant to the terms of any  agreement  or
instrument  to which any of them is a party or by which any of them may be bound
or to which any of their  property or any of them is subject  except in the case
of clauses (i)(B) or (iii) for any such conflicts,  breaches, or defaults or any
liens, charges, or encumbrances which would not have a Material Adverse Effect.

                  (e) The sale and issuance of the Securities in accordance with
the terms of and in reliance on the accuracy of the Purchaser's  representations
and warranties set forth in this Agreement will be exempt from the  registration
requirements of the Securities Act.

                  (f) No consent,  approval or  authorization of or designation,
declaration or filing with any governmental authority on the part of the Company
is  required  in  connection  with the  valid  execution  and  delivery  of this
Agreement or the offer,  sale or issuance of the Securities or the  consummation
of any other transaction contemplated by this Agreement.

                  (g)  There  is  no  action,  suit,  claim,   investigation  or
proceeding  pending or, to the knowledge of the Company,  threatened against the
Company  which  questions  the  validity  of the  Transaction  Documents  or the
transactions  contemplated  thereby or any action taken or to be taken  pursuant
thereto.  There is no action,  suit, claim,  investigation or proceeding pending
or, to the  knowledge  of the  Company,  threatened,  against or  involving  the
Company  or any  subsidiary,  or any of their  respective  properties  or assets
which,  if adversely  determined,  is reasonably  likely to result in a Material
Adverse Effect.

                  (h)  The  Company  has  complied  and  will  comply  with  all
applicable  federal  and state  securities  laws in  connection  with the offer,
issuance and sale of the Note  hereunder.  Neither the Company nor anyone acting
on its  behalf,  directly  or  indirectly,  has or will  sell,  offer to sell or
solicit offers to buy the Note, or similar securities to, or solicit offers with
respect   thereto  from,  or  enter  into  any  preliminary   conversations   or
negotiations  relating  thereto with, any person,  or has taken or will take any
action so as to bring the issuance  and sale of the Note under the  registration
provisions  of the  Securities  Act and any other  applicable  federal and state
securities laws.  Neither the Company nor any of its affiliates,  nor any person
acting on its or their behalf,  has engaged in any form of general  solicitation
or general  advertising (within the meaning of Regulation D under the Securities
Act) in connection with the Note.

                                       -4-
<PAGE>

                  (i) To the Company's  knowledge,  neither this Agreement,  nor
the Schedules  hereto contain any untrue statement of a material fact or omit to
state a material fact necessary in order to make the  statements  made herein or
therein,  in the light of the circumstances under which they were made herein or
therein, not misleading.

                  (j) The authorized capital stock of the Company and the shares
thereof issued and  outstanding as of January 20, 2006 are set forth on Schedule
3(j) attached  hereto.  All of the  outstanding  shares of the Common Stock have
been duly and validly authorized, and are fully paid and non-assessable.  Except
as set forth in this  Agreement or on Schedule 3(j) attached  hereto,  as of the
date hereof, no shares of the Common Stock are entitled to preemptive rights and
there are no registration rights or outstanding options, warrants, scrip, rights
to subscribe to, call or commitments of any character whatsoever relating to, or
securities  or rights  convertible  into,  any  shares of  capital  stock of the
Company.  As of the date hereof,  except for as set forth on Schedule  3(j), the
Company  is not a party to any  agreement  granting  registration  rights to any
person with respect to any of its equity or debt securities.  The Company is not
a party to, and its  executive  officers  have no  knowledge  of, any  agreement
restricting  the voting or transfer  of any shares of the  capital  stock of the
Company.  The  offer  and sale of all  capital  stock,  convertible  securities,
rights, warrants, or options of the Company issued prior to the Closing complied
with all applicable  federal and state  securities laws, or no stockholder has a
right of rescission or damages with respect  thereto which is reasonably  likely
to have a Material  Adverse Effect.  The Company has furnished or made available
to the  Purchaser  true and  correct  copies  of the  Company's  Certificate  of
Incorporation  as in  effect on the date  hereof  (the  "Certificate"),  and the
Company's Bylaws as in effect on the date hereof (the "Bylaws").

                  (k) So long as the Note remains outstanding, the Company shall
take all action necessary to at all times have authorized,  and reserved for the
purpose of issuance, a sufficient number of shares of Common Stock to effect the
conversion of the Note.

                  (l)  The  Company  has  complied  and  will  comply  with  all
applicable  federal  and state  securities  laws in  connection  with the offer,
issuance and sale of the Note and the Conversion Shares  hereunder.  Neither the
Company nor anyone  acting on its behalf,  directly or  indirectly,  has or will
sell,  offer to sell or solicit offers to buy any of the Securities,  or similar
securities  to, or solicit  offers with respect  thereto from, or enter into any
preliminary  conversations or negotiations relating thereto with, any person, or
has taken or will take any action so as to bring the issuance and sale of any of
the  Securities  under the  registration  provisions of the  Securities  Act and
applicable state securities laws. Neither the Company nor any of its affiliates,
nor any person acting on its or their behalf, has engaged in any form of general
solicitation  or general  advertising  (within the meaning of Regulation D under
the  Securities  Act)  in  connection  with  the  offer  or  sale  of any of the
Securities.

                  (m) The Company agrees that so long as the Note is outstanding
or the  Purchaser  owns at least  2,000,000  shares of  Common  Stock on a fully
diluted  basis,  the  Purchaser  shall have the right to  nominate or appoint an
individual to serve as an observer of the Company's board of directors.

                                       -5-
<PAGE>

         4.  Conditions  Precedent to the  Obligation of the Company to Sell the
Note. The obligation  hereunder of the Company to issue and sell the Note to the
Purchaser  is subject to the  satisfaction  or waiver,  at or before the Closing
Date, of each of the  conditions set forth below.  These  conditions are for the
Company's  sole benefit and may be waived by the Company at any time in its sole
discretion.

                  (a) The  Purchaser  shall have  executed  and  delivered  this
Agreement.

                  (b) The Purchaser shall have performed, satisfied and complied
in all material respects with all covenants,  agreements and conditions required
to be performed,  satisfied or complied with by the Purchaser at or prior to the
Closing Date.

                  (c) The  representations and warranties of the Purchaser shall
be true and correct in all material  respects as of the date when made and as of
the Closing  Date as though made at that time,  except for  representations  and
warranties that are expressly made as of a particular  date, which shall be true
and correct in all material respects as of such date.

                  (d) At the Closing Date, the Purchaser shall have delivered to
the Company immediately available funds as payment in full of the Purchase Price
for the Note.

         5. Conditions  Precedent to the Obligation of the Purchaser to Purchase
the Note. The  obligation  hereunder of the Purchaser to acquire and pay for the
Note is subject to the satisfaction or waiver, at or before the Closing Date, of
each of the conditions set forth below. These conditions are for the Purchaser's
sole  benefit  and may be  waived  by the  Purchaser  at any  time  in its  sole
discretion.

                  (a) The Company  shall have  executed and  delivered the Note,
this Agreement and any other Transaction Document.

                  (b) The Company shall have  performed,  satisfied and complied
in all material respects with all covenants,  agreements and conditions required
by the Transaction Documents to be performed,  satisfied or complied with by the
Company at or prior to the Closing Date.

                  (c) Each of the  representations and warranties of the Company
shall be true and correct in all material  respects as of the date when made and
as of the Closing Date as though made at that time  (except for  representations
and  warranties  that speak as of a  particular  date),  which shall be true and
correct in all material respects as of such date.

                  (d) No statute, regulation, executive order, decree, ruling or
injunction  shall have been  enacted,  entered,  promulgated  or endorsed by any
court or governmental  authority of competent  jurisdiction  which prohibits the
consummation  of any of the  transactions  contemplated  by this Agreement at or
prior to the Closing Date.

                  (e) As of the  Closing  Date,  no action,  suit or  proceeding
before or by any court or  governmental  agency or body,  domestic  or  foreign,
shall be pending  against or affecting  the Company,  or any of its  properties,
which  questions the validity of the  Agreement,  the Note, or the  transactions
contemplated  thereby or any action taken or to be take pursuant thereto.  As of
the Closing Date, no action, suit, claim or proceeding before or by any court or
governmental  agency or body,  domestic or foreign,  shall be pending against or
affecting the Company, or any of its properties, which, if adversely determined,
is reasonably likely to result in a Material Adverse Effect.

                  (f) No  Material  Adverse  Effect  shall have  occurred  at or
before the Closing Date.

                                       -6-
<PAGE>

                  (g) The Company  shall have  delivered  on the Closing Date to
the Purchaser a secretary's certificate, dated as of the Closing Date, as to (i)
the  resolutions  of the  board of  directors  of the  Company  authorizing  the
transactions  contemplated by this Agreement,  (ii) the  Certificate,  (iii) the
Bylaws, each as in effect at the Closing,  and (iv) the authority and incumbency
of the officers of the Company executing this Agreement and the Note.

                  (h) The  Purchaser  shall  have  received  a legal  opinion in
substantially the form annexed hereto as Exhibit B as of the Closing Date.

         6. Legend. Each Note and certificate representing the Conversion Shares
shall be stamped  or  otherwise  imprinted  with a legend  substantially  in the
following  form  (in  addition  to  any  legend  required  by  applicable  state
securities or "blue sky" laws):

                  "THE   SECURITIES   REPRESENTED  BY  THIS   CERTIFICATE   (THE
                  "SECURITIES")  HAVE NOT BEEN  REGISTERED  UNDER THE SECURITIES
                  ACT OF 1933,  AS AMENDED (THE  "SECURITIES  ACT") OR ANY STATE
                  SECURITIES LAWS AND MAY NOT BE SOLD,  TRANSFERRED OR OTHERWISE
                  DISPOSED OF UNLESS  REGISTERED  UNDER THE  SECURITIES  ACT AND
                  UNDER  APPLICABLE  STATE  SECURITIES  LAWS  OR  MEDICAL  MEDIA
                  TELEVISION,  INC.  SHALL HAVE  RECEIVED  AN OPINION OF COUNSEL
                  THAT  REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT
                  AND UNDER THE PROVISIONS OF APPLICABLE  STATE  SECURITIES LAWS
                  IS NOT REQUIRED."

The  Company  agrees  to  reissue  the Note and  certificates  representing  the
Conversion Shares,  without the legend set forth above if at such time, prior to
making any  transfer  of any such  Securities,  such holder  thereof  shall give
written  notice to the Company  describing the manner and terms of such transfer
and removal as the Company may reasonably  request.  Such proposed transfer will
not be effected until:  (a) the Company has notified such holder that either (i)
in the opinion of its counsel, the registration of the Note or Conversion Shares
under the  Securities  Act is not  required  in  connection  with such  proposed
transfer;  or (ii) a  registration  statement  under the Securities Act covering
such proposed  disposition has been filed by the Company with the Securities and
Exchange  Commission and has become  effective under the Securities Act; and (b)
the Company has  notified  such  holder that  either:  (i) in the opinion of its
counsel,  the registration or  qualification  under the securities or "blue sky"
laws of any state is not required in connection with such proposed  disposition,
or (ii) compliance with applicable  state securities or "blue sky" laws has been
effected.  The Company  will use its best  efforts to respond to any such notice
from a holder within five (5) days. In the case of any proposed  transfer  under
this Section 6, the Company will use reasonable  efforts to comply with any such
applicable  state  securities  or  "blue  sky"  laws,  but  shall in no event be
required, in connection therewith,  to qualify to do business in any state where
it is not then  qualified or to take any action that would  subject it to tax or
to the general service of process in any state where it is not then subject. The
restrictions  on transfer  contained  in this Section 6 shall be in addition to,
and not by way of limitation of, any other restrictions on transfer contained in
any other section of this Agreement.

         7. Fees and Expenses. Each party shall pay the fees and expenses of its
advisors,  counsel,  accountants  and  other  experts,  if any,  and  all  other
expenses,  incurred  by such party  incident  to the  negotiation,  preparation,
execution,  delivery and performance of this Agreement,  provided, however, that
the  Company  shall pay (i)  $10,000 of  non-accountable  fees and  expenses  in
connection  with the due  diligence,  preparation,  negotiation,  execution  and
delivery  of  this  Agreement,  the  Note  and  the  transactions   contemplated
thereunder  and (ii) the costs of any  amendments,  modifications  or waivers of
this Agreement, the Note or any other Transaction Document.

                                       -7-
<PAGE>

         8.  Indemnification.

                  (a) The Company  hereby  agrees to indemnify and hold harmless
the Purchaser and its officers, directors,  shareholders,  employees, agents and
attorneys  against  any  and  all  losses,  claims,  damages,   liabilities  and
reasonable  expenses  (collectively  "Claims")  incurred  by each such person in
connection  with  defending or  investigating  any such  Claims,  whether or not
resulting in any liability to such person,  to which any such indemnified  party
may become  subject,  insofar as such Claims  arise out of or are based upon any
breach of any  representation  or warranty or  agreement  made by the Company in
this Agreement.

                  (b) The Purchaser hereby agrees to indemnify and hold harmless
the Company and its officers,  directors,  shareholders,  employees,  agents and
attorneys against any and all losses, claims, damages,  liabilities and expenses
incurred by each such person in connection with defending or  investigating  any
such claims or  liabilities,  whether or not  resulting in any liability to such
person,  to which  any such  indemnified  party  may  become  subject  under the
Securities Act, or under any other statute, at common law or otherwise,  insofar
as such  Claims  arise  out of or are based  upon (i) any  untrue  statement  or
alleged  untrue  statement of a material  fact made by the  Purchaser,  (ii) any
omission or alleged omission of a material fact with respect to the Purchaser or
(iii) any  breach  of any  representation,  warranty  or  agreement  made by the
Purchaser in this Agreement.

         9.  Governing Law;  Consent to  Jurisdiction.  This Agreement  shall be
governed by and  interpreted in accordance with the laws of the State of Florida
without giving effect to the rules  governing the conflicts of laws. Each of the
parties  consents to the  exclusive  jurisdiction  of the Federal  courts  whose
districts  encompass any part of the County of Hillsborough  located in the City
of Tampa in connection  with any dispute arising under this Agreement and hereby
waives,  to the maximum extent  permitted by law, any  objection,  including any
objection based on forum non conveniens,  to the bringing of any such proceeding
in such  jurisdictions.  Each party  waives  its right to a trial by jury.  Each
party to this  Agreement  irrevocably  consents to the service of process in any
such  proceeding  by the mailing of copies  thereof by  registered  or certified
mail,  postage prepaid,  to such party at its address set forth herein.  Nothing
herein shall affect the right of any party to serve  process in any other manner
permitted by law.

         10.  Notices.  All notices  and other  communications  provided  for or
permitted hereunder shall be made in writing by hand delivery, express overnight
courier,  registered  first class mail, or telecopier  (provided that any notice
sent by  telecopier  shall be confirmed by other means  pursuant to this Section
10),  initially to the address set forth  below,  and  thereafter  at such other
address,  notice of which is given in  accordance  with the  provisions  of this
Section.

                  (a) if to the Company:

                      Medical Media Television, Inc.
                      8406 Benjamin Road, Suite C
                      Tampa, Florida 33634
                      Attention: Philip M. Cohen, President/Chief Executive
                      Officer
                      Tel. No.: (813) 888-7330
                      Fax No.:  (813) 888-7375

                                       -8-
<PAGE>

                  with a copy to:

                      Bush Ross Gardner Warren & Rudy, P.A.
                      220 S. Franklin St.
                      Tampa, FL  33601
                      Attn:  John N. Giordano
                      Tel. No.:  (813) 224-9255
                      Fax No.:  (813) 223-9620

                  (b) if to the Purchaser:

                      William H. Quiros
                      1112 League Line Rd
                      Conroe, TX 77303
                      Tel. No.:  (818) 284-0496
                      Fax No.:  (708) 575-7985

All such  notices  and  communications  shall be deemed to have been duly given:
when delivered by hand, if personally  delivered;  when receipt is acknowledged,
if telecopied; or when actually received or refused if sent by other means.

         11.  Assignment.  Neither  party may assign,  sell,  or transfer to any
third  person  the  rights of such  party  hereunder;  provided,  however,  that
Purchaser  may  assign  his  rights  hereunder  to an  entity  wholly  owned and
controlled by Purchaser.

         12.  Entire  Agreement.   This  Agreement,   the  Note  and  any  other
Transaction  Document  constitute the entire  understanding and agreement of the
parties  with  respect to the subject  matter  hereof and  supersedes  all prior
and/or  contemporaneous oral or written proposals or agreements relating thereto
all of which  are  merged  herein.  This  Agreement  may not be  amended  or any
provision  hereof  waived in whole or in part,  except  by a  written  amendment
signed by both of the parties.

         13. Counterparts. This Agreement may be executed by facsimile signature
and in counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

                                  [End of page]

                                       -9-
<PAGE>

         IN WITNESS  WHEREOF,  the Company and Payee have executed and delivered
this Note  Purchase  Agreement as of July 26, 2006 with an effective  date as of
the date first written above.

                                MEDICAL MEDIA TELEVISION, INC.

                                By: /s/ Philip M. Cohen
                                    --------------------------------------------
                                     Name: Philip M. Cohen
                                     Title:   President and Chief Executive
                                              Officer

                                PURCHASER:

                                /s/ William H. Quiros
                                ------------------------------------------------
                                      William H. Quiros

                                      -10-
<PAGE>

                                    EXHIBIT A
                                    ---------
                                  FORM OF NOTE

                                      -11-
<PAGE>

                                    EXHIBIT B
                                    ---------
                                 FORM OF OPINION

         1. The Company is a corporation duly incorporated, validly existing and
in good  standing  under the laws of the State of Florida and has the  requisite
corporate  power to own,  lease and operate its  properties  and assets,  and to
carry on its business as presently conducted. The Company is duly qualified as a
foreign corporation to do business and is in good standing in every jurisdiction
in which the failure to so qualify would have a Material Adverse Effect.

         2. The Company has the requisite corporate power and authority to enter
into and perform its obligations  under the  Transaction  Documents and to issue
the  Securities.  The execution,  delivery and  performance  of the  Transaction
Documents  by  the  Company  and  the  consummation  by it of  the  transactions
contemplated  thereby  have been duly and validly  authorized  by all  necessary
corporate  action and no further consent or  authorization of the Company or its
Board of  Directors  is  required.  The  Transaction  Documents  have  been duly
executed  and  delivered,  and the Note  has  been  duly  executed,  issued  and
delivered  by the Company and each  Transaction  Document  constitutes  a legal,
valid and binding obligation of the Company  enforceable  against the Company in
accordance with its respective  terms. The Conversion  Shares are not subject to
any preemptive rights under the Certificate of Incorporation or the Bylaws.

         3. The Note  has been  duly  authorized  and,  when  delivered  against
payment in full as provided in the Purchase  Agreement,  will be validly issued.
The Conversion Shares have been duly authorized for issuance, and when delivered
upon  conversion  or against  payment in full as provided  in the Note,  will be
validly issued, fully paid and nonassessable.

         4. The execution,  delivery and  performance of and compliance with the
terms of the Transaction Documents and the issuance of the Securities do not (a)
violate any provision of the Certificate of Incorporation or Bylaws,  (b) to our
knowledge,  after due inquiry,  conflict  with,  or  constitute a default (or an
event which with notice or lapse of time or both would become a default)  under,
or  give to  others  any  rights  of  termination,  amendment,  acceleration  or
cancellation of, any material  agreement,  mortgage,  deed of trust,  indenture,
note,  bond,  license,  lease  agreement,  instrument or obligation to which the
Company  is a party and which is known to us,  (c) to our  knowledge,  after due
inquiry,  create or impose a lien,  charge or encumbrance on any property of the
Company under any agreement or any  commitment  known to us to which the Company
is a party or by which the  Company  is bound or by which any of its  respective
properties  or assets are bound,  or (d) result in a violation  of any  Federal,
state, local or foreign statute, rule, regulation,  order, judgment,  injunction
or  decree  (including  Federal  and  state  securities  laws  and  regulations)
applicable  to the  Company or by which any  property or asset of the Company is
bound or  affected,  except,  in all cases  other than  violations  pursuant  to
clauses  (a)  and  (d)  above,  for  such  conflicts,   default,   terminations,
amendments,   acceleration,   cancellations   and   violations   as  would  not,
individually or in the aggregate, have a Material Adverse Effect.

         5. No consent, approval or authorization of or designation, declaration
or filing with any governmental authority on the part of the Company is required
under  Federal,  state or local law, rule or  regulation in connection  with the
valid execution,  delivery and performance of the Transaction Documents,  or the
offer, sale or issuance of the Note or the Conversion Shares.

                                      -12-
<PAGE>

         6. To our knowledge,  there is no action, suit, claim, investigation or
proceeding  pending or  threatened  against  the  Company  which  questions  the
validity of the Purchase Agreement or the transactions  contemplated  thereby or
any action  taken or to be taken  pursuant  thereto.  There is no action,  suit,
claim,  investigation or proceeding  pending,  or to our knowledge,  threatened,
against or involving  the Company or any of its  properties or assets and which,
if adversely  determined,  is reasonably  likely to result in a Material Adverse
Effect.  There are no  outstanding  orders,  judgments,  injunctions,  awards or
decrees of any court,  arbitrator or governmental or regulatory body against the
Company or any officers or directors of the Company in their capacities as such.

         7. Conditioned on the accuracy of the Purchaser's  representations  and
warranties contained in the Purchase Agreement,  the offer, issuance and sale of
the Note and the offer,  issuance and sale of the Conversion  Shares pursuant to
the  Purchase  Agreement  and the  Note,  as  applicable,  are  exempt  from the
registration requirements of the Securities Act of 1933, as amended.

                                      -13-
<PAGE>

                                   SCHEDULE 3j
                                   -----------

Medical Media Television, Inc. Capital Stock:

Common Stock:              Authorized Shares:            100,000,000 shares
                           Outstanding Shares:            20,971,299 shares
                           Par Value:                     $.0005

Preferred Stock:           Total Authorized Shares:      25,000,000 shares
                           Total Outstanding Shares:      4,303,959 shares
                           Par Value:                     Zero

Series A Zero Coupon Preferred Stock:   Authorized Shares:      1,682,044 shares
                                        Outstanding Shares:     1,682,044 shares

Series B Zero Coupon Preferred Stock:   Authorized Shares:      2,612,329 shares
                                        Outstanding Shares:     2,612,329 shares

Series C Zero Coupon Preferred Stock:   Authorized Shares:        400,000 shares
                                        Outstanding Shares:         8,627 shares

      OUTSTANDING OPTIONS, WARRANTS, AND OTHER RIGHTS TO ACQUIRE SHARES OF
                         MEDICAL MEDIA TELEVISION, INC.

Outstanding stock options to purchase 5,303 shares of common stock of MMTV.

Outstanding warrants to purchase 10,879,235 shares of common stock of MMTV.

Outstanding  Series A and Series B  preferred  shares  which will  convert  into
16,093,989 shares of common stock of MMTV.

Outstanding  Series C preferred  shares  (8,627)  which will convert into common
shares at a discount to market at time of conversion.

Outstanding  convertible  debentures which will convert into 6,987,952 shares of
common stock of MMTV. These convertible  debentures may be repaid in cash at the
option of the Company.

The above  calculations  do not include  any shares of Series C preferred  stock
that  may  be  issued  for  interest  payments  on  existing   convertible  debt
instruments that will be converted into common shares at a discount to market at
time of  conversion.  It also does not  include  any common  shares  that may be
issued for interest payments on existing convertible debt instruments.

                                      -14-Exh. 10.8 - Quiros Promissory Note dated March 31, 2006 for $450,000

THIS CONVERTIBLE PROMISSORY NOTE IS BEING ISSUED TO WILLIAM H. QUIROS AS A CARVE
OUT  FROM  THE  CONVERTIBLE   PROMISSORY  NOTE  ISSUED  TO   CAPITALSMART,   LLC
("CAPITALSMART  NOTE") DATED FEBRUARY 15, 2006 FOR $1,000,000.  PER AN AGREEMENT
BETWEEN THE PRINCIPALS OF CAPITALSMART, LLC, THE CAPITALSMART NOTE WAS CANCELLED
AND INDIVIDUAL CONVERTIBLE PROMISSORY NOTES WERE ISSUED IN LIEU THEREOF, EACH IN
THE NAME OF A PRINCIPAL (OR ENTITY CONTROLLED BY A PRINCIPAL) OF CAPITALSMART.

THIS NOTE HAS NOT BEEN  REGISTERED  UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE  "SECURITIES  ACT"),  OR ANY  STATE  SECURITIES  LAW AND  MAY NOT BE  SOLD,
TRANSFERRED OR OTHERWISE  DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT
AND UNDER  APPLICABLE STATE  SECURITIES LAWS OR MEDICAL MEDIA  TELEVISION,  INC.
SHALL HAVE RECEIVED AN OPINION OF COUNSEL THAT  REGISTRATION  OF SUCH SECURITIES
UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES
LAWS IS NOT REQUIRED.

                         MEDICAL MEDIA TELEVISION, INC.

                           CONVERTIBLE PROMISSORY NOTE

U.S. $450,000                                                     March 31, 2006
No.: PN-0331-SRP

            FOR VALUE RECEIVED, the undersigned, Medical Media Television, Inc.,
a Florida  corporation (the  "Company"),  hereby promises to pay to the order of
William H. Quiros or any future  permitted  holder of this  promissory note (the
"Investor",  "Payee",  or "Holder"),  at the  principal  office of the Payee set
forth  herein,  or at such other place as the Payee may  designate in writing to
the Company,  the  principal sum of Four Hundred  Fifty  Thousand  Dollars (U.S.
$450,000),  or such other amount as may be outstanding hereunder,  together with
any accrued but unpaid  interest,  in such coin or currency of the United States
of America as at the time  shall be legal  tender for the  payment of public and
private  debts  and  in  immediately   available  funds,  as  provided  in  this
Convertible  Promissory Note (the "Note").  This Note is the Note referred to in
the Note Purchase  Agreement dated as of March 30, 2006, between the Company and
the purchaser named therein (the "Purchase  Agreement").  Capitalized terms used
and not  otherwise  defined  herein  shall have the  meanings set forth for such
terms in the Purchase Agreement.

            1. Principal and Interest Payments.

                  (a) The Payee  shall loan the  Company,  in  installments,  an
aggregate of $450,000.

                  (b) The  Company  shall  repay  in full the  entire  principal
balance then  outstanding  under this Note plus any accrued but unpaid  interest
and any Applied Interest as outlined in 1(c) below: (i) at any time on or before
March 30,  2009,  or (ii) as this  Note may be  extended  pursuant  to the terms
hereof,  or (iii) upon the  acceleration  of the  obligations as contemplated by
this Note, all being described as the "Maturity Date."
<PAGE>

                  (c) The Note shall bear  interest at a rate of twenty  percent
(20%) per annum.  Until such time as all installments  representing an aggregate
of $450,000 have been paid to the Company by the Payee, interest hereunder shall
be paid on a quarterly  basis with the said  interest  payment(s)  being applied
toward the balance  remaining unpaid ("Applied  Interest").  At such time as the
entire  $450,000  has been  received by the Company  [via cash  payments  and/or
Applied  Interest],  then all future interest shall accrue,  but will not become
due and payable until the Maturity Date.

                  (d) This Note  shall  not be  convertible  until the  Maturity
Date.  With the consent of both the Company  and the  Investor,  the Note may be
extended  for an  additional  12-month  term,  with the  terms  of the  interest
payments  remaining  the same as outlined  in 1(c) above.  The Note shall not be
convertible such that the Investor's  overall Common Stock ownership position in
the Company exceeds 4.99%.

                  (e) The Company has the option to pay the principal  amount of
this Note plus any  accrued but unpaid  interest  in a cash  payment at any time
prior to the Maturity Date.

            2. Conversion Option; Issuance of Certificates.

                  (a) This Note  shall  not be  convertible  until the  Maturity
Date. If the Company has not paid the Note prior to the Maturity  Date,  then at
the Maturity  Date,  the  outstanding  principal  amount of this Note,  plus any
accrued but unpaid interest shall be due and payable in cash; provided, however,
the  Payee  shall  have the sole  option to  convert  on the  Maturity  Date the
outstanding  principal  amount of this Note plus any accrued but unpaid interest
and any  Applied  Interest  into such  number  of shares of common  stock of the
Company, par value $.0005 per share (the "Common Stock"), equal to the principal
amount of this Note plus any accrued but unpaid  interest  and Applied  Interest
being  converted  divided by the  Conversion  Price.  For purposes of this Note,
"Conversion  Price"  shall  mean the  amount  equal to a  twenty  percent  (20%)
discount to the then-current market price based on the average closing price for
the twenty (20) days immediately preceding the conversion, but in no event shall
the Conversion Price be less than $0.166 per share. Upon conversion of this Note
into shares of Common  Stock,  the  outstanding  principal  amount of this Note,
together  with any accrued but unpaid  interest and Applied  Interest,  shall be
deemed to be the consideration for the Payee's interest in such shares of Common
Stock.

                  (b) In the event that the Payee  elects to  convert  this Note
into shares of Common Stock in accordance with Section 2(a) herein,  the Company
shall,  not later than five (5) trading days after the  conversion of this Note,
issue and deliver to the Payee by express  courier a certificate or certificates
representing  the  number  of shares of Common  Stock  being  acquired  upon the
conversion of this Note.

            3. Ownership Cap and Certain Exercise Restrictions.

                  (a) Notwithstanding anything to the contrary set forth in this
Note,  at no time may a Holder of this Note  convert  this Note if the number of
shares of Common Stock to be issued  pursuant to such  conversion  would exceed,
when  aggregated  with all other  shares of Common Stock owned by such Holder at
such  time,  the number of shares of Common  Stock  which  would  result in such
Holder  owning more than 4.999% of all of the Common Stock  outstanding  at such
time; provided,  however,  that upon a holder of this Note providing the Company
with  sixty-one  (61) days notice  (pursuant  to Section 13 hereof) (the "Waiver
Notice")  that such Holder  would like to waive this Section 3(a) with regard to
any or all shares of Common  Stock  issuable  upon  exercise of this Note,  this
Section  3(a) will be of no force or effect  with  regard to all or a portion of
the Note referenced in the Waiver Notice; provided, further, that this provision
shall  be of  no  further  force  or  effect  during  the  sixty-one  (61)  days
immediately preceding the expiration of the term of this Note.

                                        2
<PAGE>

                  (b) The  Holder may not  convert  this Note  hereunder  to the
extent  such  conversion  would  result in the  Holder  beneficially  owning (as
determined  in  accordance  with Section 13(d) of the Exchange Act and the rules
thereunder)  in excess of 9.999% of the then  issued and  outstanding  shares of
Common Stock,  including shares issuable upon conversion of the Note held by the
Holder after application of this Section; provided,  however, that upon a holder
of this Note  providing  the Company with a Waiver Notice that such holder would
like to waive this Section 3(b) with regard to any or all shares of Common Stock
issuable upon conversion of this Note, this Section 3(b) shall be of no force or
effect  with regard to those  shares of Common  Stock  referenced  in the Waiver
Notice;  provided,  further, that this provision shall be of no further force or
effect during the sixty-one  (61) days  immediately  preceding the expiration of
the term of this Note.

            4. Responsibilities of Company:

                  (a) Issue Taxes.  The Company  shall pay any and all issue and
other taxes, excluding federal, state or local income taxes, that may be payable
in respect of any issue or delivery of shares of Common Stock on  conversion  of
this Note pursuant  thereto;  provided,  however,  that the Company shall not be
obligated to pay any transfer taxes resulting from any transfer requested by any
holder in connection with any such conversion.

                  (b) Fractional  Shares.  No fractional  shares of Common Stock
shall be issued upon  conversion of this Note. In lieu of any fractional  shares
to which the Payee would otherwise be entitled, the Company shall pay cash equal
to the  product of such  fraction  multiplied  by the average of the closing bid
prices of the Common Stock for the five (5) consecutive trading days immediately
preceding the date of conversion of this Note.

                  (c)  Reservation  of Common  Stock.  The Company  shall at all
times when this Note shall be outstanding, reserve and keep available out of its
authorized but unissued shares of Common Stock,  such number of shares of Common
Stock as shall from time to time be sufficient to effect the  conversion of this
Note.

                  (d)  Registration  Rights.  The  Investor  is  aware  that the
Company  filed a  Registration  Statement on Form SB-2 which was approved by the
Securities & Exchange  Commission on March 1, 2006 and that a total of 2,500,000
shares of Common Stock were reserved and  registered  for the  conversion of the
original CapitalSmart  Convertible Promissory Note for $1,000,000.  The Investor
acknowledges  and understands  that 1,125,000  shares of Common Stock previously
registered has been allocated for the future  conversion of the principal amount
of this Note, plus all accrued but unpaid interest and any Applied Interest (the
"Allocated Shares").  Any shares of Common Stock issued to the Investor upon the
conversion  of the  principal  amount of this Note plus all  accrued  but unpaid
interest and any Applied  Interest in excess of the Allocated  Shares shall have
standard piggyback registration rights.

            5. No Rights as Shareholder. Nothing contained in this Note shall be
construed as conferring  upon the Payee,  prior to the  conversion of this Note,
the right to vote or to receive  dividends or to consent or to receive notice as
a  shareholder  in respect of any meeting of  shareholders  for the  election of
directors  of the  Company  or of any other  matter,  or any  other  rights as a
shareholder of the Company.

                                        3
<PAGE>

            6.  Payment on  Non-Business  Days.  Whenever any payment to be made
shall be due on a  Saturday,  Sunday or a public  holiday  under the laws of the
State of Florida, such payment may be due on the next succeeding business day.

            7.  Representations  and  Warranties  of the  Company.  The  Company
represents and warrants to the Payee as follows:

                  (a) The Company has been duly  incorporated,  validly  exists,
and is in good  standing  under  the laws of the  State of  Florida,  with  full
corporate  power and authority to own,  lease and operate its  properties and to
conduct its business as currently conducted.

                  (b) This Note has been duly  authorized,  validly executed and
delivered on behalf of the Company and is a valid and binding  obligation of the
Company enforceable against the Company in accordance with its terms, subject to
limitations on enforcement by general  principles of equity and by bankruptcy or
other laws affecting the  enforcement of creditors'  rights  generally,  and the
Company has full power and  authority  to execute  and deliver  this Note and to
perform its obligations hereunder.

                  (c) The execution,  delivery and performance of this Note will
not (i)  conflict  with or result  in a breach of or a default  under any of the
terms or  provisions  of, (A) the  Company's  certificate  of  incorporation  or
by-laws, or (B) any material provision of any indenture, mortgage, deed of trust
or other material  agreement or instrument to which the Company is a party or by
which it or any of its material  properties or assets is bound, (ii) result in a
violation of any material provision of any law, statute,  rule,  regulation,  or
any existing applicable decree, judgment or order by any court, Federal or state
regulatory  body,  administrative  agency,  or other  governmental  body  having
jurisdiction  over the Company,  or any of its material  properties or assets or
(iii)  result in the creation or  imposition  of any  material  lien,  charge or
encumbrance  upon any  material  property or assets of the Company or any of its
subsidiaries  pursuant to the terms of any  agreement or instrument to which any
of them is a party or by which any of them may be bound or to which any of their
property or any of them is subject.

                  (d) No consent,  approval or  authorization of or designation,
declaration or filing with any governmental authority on the part of the Company
is required in connection with the valid execution and delivery of this Note.

            8. Events of Default.  The occurrence of any of the following events
shall be an "Event of Default" under this Note:

                  (a) the  Company  shall fail to make the payment of any amount
of any  principal  outstanding  on the date such  payment  shall  become due and
payable hereunder; or

                  (b) the Company  shall fail to make  interest  payments on the
date such payments shall become due and payable hereunder; or

                  (c) any representation,  warranty or certification made by the
Company herein, or in any certificate or financial statement shall prove to have
been false or  incorrect  or  breached  in a material  respect on the date as of
which made; or

                                        4
<PAGE>

                  (d) the holder of any  indebtedness  of the  Company or any of
its  subsidiaries  shall  accelerate  any  payment  of any  amount or amounts of
principal or interest on any indebtedness (the  "Indebtedness")  (other than the
Indebtedness  hereunder)  prior  to its  stated  maturity  or  payment  date the
aggregate  principal  amount of which  Indebtedness  of all such  persons  is in
excess of $100,000, whether such Indebtedness now exists or shall hereinafter be
created,  and such accelerated  payment entitles the holder thereof to immediate
payment of such  Indebtedness  which is due and owing and such  indebtedness has
not been discharged in full or such acceleration has not been stayed,  rescinded
or annulled within ten (10) business days of such acceleration; or

                  (e) a  judgment  or order for the  payment  of money  shall be
rendered against the Company or any of its subsidiaries in excess of $100,000 in
the aggregate (net of any applicable  insurance coverage) for all such judgments
or orders against all such persons (treating any deductibles,  self insurance or
retention  as not so  covered)  that  shall  not be  discharged,  and  all  such
judgments and orders remain outstanding,  and there shall be any period of sixty
(60)  consecutive  days  following  entry of the  judgment or order in excess of
$500,000 or the judgment or order which causes the  aggregate  amount  described
above to exceed  $500,000 during which a stay of enforcement of such judgment or
order, by reason of a pending appeal or otherwise, shall not be in effect; or

                  (f)  the  Company  shall  (i)  apply  for  or  consent  to the
appointment of, or the taking of possession by, a receiver,  custodian,  trustee
or  liquidator  of itself or of all or a  substantial  part of its  property  or
assets,  (ii)  admit in  writing  its  inability  to pay its debts as such debts
become due,  (iii) make a general  assignment  for the benefit of its creditors,
(iv) commence a voluntary case under the Bankruptcy Code or under the comparable
laws of any jurisdiction  (foreign or domestic),  (v) file a petition seeking to
take advantage of any  bankruptcy,  insolvency,  moratorium,  reorganization  or
other similar law affecting the enforcement of creditors' rights generally, (vi)
acquiesce in writing to any petition  filed  against it in an  involuntary  case
under the  Bankruptcy  Code or under  the  comparable  laws of any  jurisdiction
(foreign  or  domestic),  or  (vii)  take  any  action  under  the  laws  of any
jurisdiction (foreign or domestic) analogous to any of the foregoing; or

                  (g) a proceeding  or case shall be commenced in respect of the
Company or any of its  subsidiaries  without its application or consent,  in any
court of competent  jurisdiction,  seeking (i) the liquidation,  reorganization,
moratorium,  dissolution,  winding up, or  composition  or  readjustment  of its
debts, (ii) the appointment of a trustee, receiver, custodian, liquidator or the
like of it or of all or any  substantial  part of its  assets  or (iii)  similar
relief in respect of it under any law providing  for the relief of debtors,  and
such  proceeding or case  described in clause (i), (ii) or (iii) shall  continue
undismissed,  or unstayed and in effect, for a period of thirty (30) consecutive
days or any order for relief shall be entered in an  involuntary  case under the
Bankruptcy  Code or under the comparable  laws of any  jurisdiction  (foreign or
domestic)  against the Company or any of its  subsidiaries  or action  under the
laws of any jurisdiction (foreign or domestic) analogous to any of the foregoing
shall be taken with respect to the Company or any of its  subsidiaries and shall
continue  undismissed,  or  unstayed  and in effect for a period of thirty  (30)
consecutive days; or

                  (h) failure by the Company to issue the  Conversion  Shares or
notice from the Company to the Payee,  including by way of public  announcement,
at any time,  of its  inability  to comply or its  intention  not to comply with
proper requests for conversion of this Note into shares of Common Stock.

                                        5
<PAGE>

            9. Remedies  Upon An Event of Default.  If an Event of Default shall
have occurred and shall be continuing, the Payee of this Note may at any time at
its  option,  (a)  declare  the entire  unpaid  principal  balance of this Note,
together with all accrued but unpaid interest,  due and payable,  and thereupon,
the same shall be accelerated and so due and payable;  provided,  however,  that
upon the  occurrence of an Event of Default  described in Sections 8(f) and (g),
without  presentment,  demand,  protest,  or  notice,  all of which  are  hereby
expressly unconditionally and irrevocably waived by the Company, the outstanding
principal balance and any accrued but unpaid interest shall be automatically due
and payable; or (b) exercise or otherwise enforce any one or more of the Payee's
rights, powers, privileges, remedies and interests under this Note or applicable
law.  No  course  of delay on the part of the Payee  shall  operate  as a waiver
thereof  or  otherwise  prejudice  the right of the Payee.  No remedy  conferred
hereby  shall be  exclusive  of any other  remedy  referred  to herein or now or
hereafter available at law, in equity, by statute or otherwise.  Notwithstanding
the foregoing,  Payee agrees that its rights and remedies  hereunder are limited
to receipt of cash or shares of Common Stock in the amounts described herein.

            10.  Replacement.  Upon receipt of a duly  executed,  notarized  and
unsecured  written  statement from the Payee with respect to the loss,  theft or
destruction of this Note (or any replacement  hereof),  and without requiring an
indemnity bond or other security,  or, in the case of a mutilation of this Note,
upon  surrender  and  cancellation  of such Note,  the Company shall issue a new
Note,  of like tenor and  amount,  in lieu of such lost,  stolen,  destroyed  or
mutilated Note.

            11. Parties in Interest, Transferability. This Note shall be binding
upon the Company and its successors and assigns and the terms hereof shall inure
to the benefit of the Payee and its successors and permitted assigns.  This Note
may be transferred or sold,  subject to the provisions of this Note, or pledged,
hypothecated or otherwise granted as security by the Payee.

            12.  Amendments.  This Note may not be  modified  or  amended in any
manner except in writing executed by the Company and the Payee.

            13. Assignment.  Neither party may assign,  sell, or transfer to any
third person the rights of such party hereunder;  provided,  however, that Payee
may assign his rights  hereunder  to an entity  wholly owned and  controlled  by
Payee.

            14.  Notices.  Any  notice,   demand,   request,   waiver  or  other
communication  required or permitted to be given  hereunder  shall be in writing
and shall be  effective  (a) upon hand  delivery by telecopy or facsimile at the
address or number designated below (if delivered on a business day during normal
business  hours where such notice is to be received),  or the first business day
following such delivery (if delivered other than on a business day during normal
business  hours  where  such  notice  is to be  received)  or (b) on the  second
business day following  the date of mailing by express  courier  service,  fully
prepaid,  addressed to such  address,  or upon actual  receipt of such  mailing,
whichever  shall first occur.  The Company will give written notice to the Payee
at least  thirty  (30) days  prior to the date on which the  Company  closes its
books and in no event shall such notice be provided to such holder prior to such
information  being made known to the public.  The Company will also give written
notice  to the  Payee  at  least  twenty  (20)  days  prior to the date on which
dissolution,  liquidation  or  winding-up  will take place and in no event shall
such notice be provided to the Payee prior to such information  being made known
to the public.

         Address of the Payee:      William H. Quiros
                                    1112 League Line Rd
                                    Conroe, TX 77303
                                    Tel. No.: (818) 284-0496
                                    Fax No.: (708) 575-7985

                                        6
<PAGE>

         Address of the Company:    Medical Media Television, Inc.
                                    8406 Benjamin Road, Suite C
                                    Tampa, Florida 33634
                                    Attention: Philip M. Cohen, President/CEO
                                    Tel. No.:  (813) 888-7330
                                    Fax No.:  (813) 888-7375

                  with a copy to:   Bush Ross Gardner Warren & Rudy, PA
                                    Attn:  John N. Giordano
                                    220 S. Franklin St.
                                    Tampa, FL  33601
                                    Tel. No.:  (813) 224-9255
                                    Fax No.:  (813) 223-9620

            15.  Governing  Law. This Note shall be governed by and construed in
accordance with the internal laws of the State of Florida, without giving effect
to the choice of law provisions. This Note shall not be interpreted or construed
with any presumption against the party causing this Note to be drafted.

            16. Headings. Article and section headings in this Note are included
herein for purposes of  convenience of reference only and shall not constitute a
part of this Note for any other purpose.

            17. Remedies,  Characterizations,  Other  Obligations,  Breaches and
Injunctive Relief. The remedies provided in this Note shall be cumulative and in
addition to all other  remedies  available  under this Note, at law or in equity
(including,  without limitation,  a decree of specific  performance and/or other
injunctive  relief),  no  remedy  contained  herein  shall be deemed a waiver of
compliance  with the  provisions  giving rise to such remedy and nothing  herein
shall  limit a Payee's  right to pursue  actual  damages  for any failure by the
Company to comply with the terms of this Note. Amounts set forth or provided for
herein with respect to payments and the like (and the computation thereof) shall
be the amounts to be received  by the Payee and shall not,  except as  expressly
provided  herein,  be subject to any other  obligation  of the  Company  (or the
performance  thereof).  The  Company  acknowledges  that a  breach  by it of its
obligations  hereunder will cause irreparable and material harm to the Payee and
that the remedy at law for any such  breach  may be  inadequate.  Therefore  the
Company agrees that, in the event of any such breach or threatened  breach,  the
Payee shall be entitled, in addition to all other available rights and remedies,
at law or in equity, to seek and obtain such equitable relief, including but not
limited to an  injunction  restraining  any such  breach or  threatened  breach,
without the  necessity  of showing  economic  loss and without any bond or other
security being required.

            18.  Failure or  Indulgence  Not Waiver.  No failure or delay on the
part of the Payee in the  exercise of any power,  right or  privilege  hereunder
shall operate as a waiver thereof,  nor shall any single or partial  exercise of
any such power, right or privilege preclude other or further exercise thereof or
of any other right, power or privilege.

            19.  Enforcement  Expenses.  The Company agrees to pay all costs and
expenses of enforcement of this Note, including, without limitation,  reasonable
attorneys' fees and expenses.

            20. Binding Effect. The obligations of the Company and the Payee set
forth  herein  shall be binding  upon the  successors  and  assigns of each such
party,  whether or not such  successors  or assigns are  permitted  by the terms
hereof.

                                        7
<PAGE>

            21.  Compliance  with  Securities  Laws.  The  Payee  of  this  Note
acknowledges that this Note is being acquired solely for the Payee's own account
and not as a nominee for any other party, and for investment, and that the Payee
shall not offer, sell or otherwise dispose of this Note other than in compliance
with the laws of the United  States of America and as guided by the rules of the
Securities  and  Exchange   Commission.   This  Note  and  any  Note  issued  in
substitution  or  replacement  therefore  shall be stamped or  imprinted  with a
legend in substantially the following form:

                  "THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
                  1933,  AS  AMENDED  (THE  "SECURITIES   ACT"),  OR  ANY  STATE
                  SECURITIES  LAW AND MAY NOT BE SOLD,  TRANSFERRED OR OTHERWISE
                  DISPOSED OF UNLESS  REGISTERED  UNDER THE  SECURITIES  ACT AND
                  UNDER  APPLICABLE  STATE  SECURITIES  LAWS  OR  MEDICAL  MEDIA
                  TELEVISION,  INC.  SHALL HAVE  RECEIVED  AN OPINION OF COUNSEL
                  THAT  REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT
                  AND UNDER THE PROVISIONS OF APPLICABLE  STATE  SECURITIES LAWS
                  IS NOT REQUIRED."

            22. Severability.  The provisions of this Note are severable, and if
any provision shall be held invalid or  unenforceable in whole or in part in any
jurisdiction,  then such invalidity or unenforceability  shall not in any manner
affect such provision in any other  jurisdiction  or any other provision of this
Note in any jurisdiction.

            23. Consent to  Jurisdiction.  Each of the Company and the Payee (i)
hereby  irrevocably  submits to the  jurisdiction  of the United States District
Court sitting in Central  Florida and the courts of the State of Florida located
in  Hillsborough  County  for the  purposes  of any suit,  action or  proceeding
arising out of or relating to this Note and (ii) hereby  waives,  and agrees not
to  assert in any such  suit,  action or  proceeding,  any claim  that it is not
personally  subject to the jurisdiction of such court,  that the suit, action or
proceeding  is brought in an  inconvenient  forum or that the venue of the suit,
action or proceeding is improper.  Each of the Company and the Payee consents to
process  being served in any such suit,  action or  proceeding by mailing a copy
thereof to such party at the  address  set forth in Section 13 hereof and agrees
that such service shall  constitute  good and sufficient  service of process and
notice  thereof.  Nothing in this  Section 23 shall affect or limit any right to
serve process in any other manner permitted by law.

            24.  Company  Waivers.  Except as  otherwise  specifically  provided
herein, the Company and all others that may become liable for all or any part of
the obligations evidenced by this Note, hereby waive presentment, demand, notice
of nonpayment,  protest and all other demands and notices in connection with the
delivery,  acceptance,  performance  and enforcement of this Note, and do hereby
consent to any number of renewals of  extensions  of the time or payment  hereof
and agree that any such renewals or extensions may be made without notice to any
such persons and without affecting their liability herein and do further consent
to the release of any person liable hereon,  all without affecting the liability
of the other persons,  firms or Company liable for the payment of this Note, AND
DO HEREBY WAIVE TRIAL BY JURY.

                  (a)  No  delay  or  omission  on the  part  of  the  Payee  in
exercising  its rights under this Note,  or course of conduct  relating  hereto,
shall  operate as a waiver of such rights or any other  right of the Payee,  nor
shall any waiver by the Payee of any such right or rights on any one occasion be
deemed a waiver of the same right or rights on any future occasion.

                                        8
<PAGE>

                  (b) THE COMPANY  ACKNOWLEDGES  THAT THE  TRANSACTION  OF WHICH
THIS NOTE IS A PART IS A COMMERCIAL  TRANSACTION,  AND TO THE EXTENT  ALLOWED BY
APPLICABLE  LAW,  HEREBY  WAIVES ITS RIGHT TO NOTICE AND HEARING WITH RESPECT TO
ANY  PREJUDGMENT  REMEDY WHICH THE PAYEE OR ITS SUCCESSORS OR ASSIGNS MAY DESIRE
TO USE.

            IN WITNESS WHEREOF, the Company has executed and delivered this Note
as of July 26, 2006 with an effective date as of the date first written above.

                               MEDICAL MEDIA TELEVISION, INC.

                               By: /s/ Philip M. Cohen
                                   ---------------------------------------------
                                    Name:  Philip M. Cohen
                                    Title: President and Chief Executive Officer

                                        9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}]]